购物车
全部删除
您的购物车当前为空
别名 伊匹单抗
Ipilimumab 是全人类单克隆抗体 IgG1κ,能够抗 CTLA-4。其中CTLA-4是一种由活化的 T 细胞产生的免疫抑制分子。


为众多的药物研发团队赋能,
让新药发现更简单!
Ipilimumab 是全人类单克隆抗体 IgG1κ,能够抗 CTLA-4。其中CTLA-4是一种由活化的 T 细胞产生的免疫抑制分子。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 4,390 | 现货 | |
| 2 mg | ¥ 6,260 | 现货 | |
| 5 mg | ¥ 9,470 | 现货 | |
| 10 mg | ¥ 12,700 | 现货 | |
| 25 mg | ¥ 18,800 | 现货 | |
| 50 mg | ¥ 25,300 | 现货 |
| 产品描述 | Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. |
| 细胞实验 | Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Concentrations: 0, 0.5, 5.0, and 50 μg/mL. Incubation Time: 10-14 days. Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt's lymphoma cell line (Daudi). |
| 动物实验 | Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas. Formulation: PBS. Dosages: 100 μg, three times weekly |
| 别名 | 伊匹单抗 |
| 反应种属 | Human |
| 应用 | ELISA FCM Functional assay |
| 抗体种类 | Monoclonal |
| 内毒素 | <1.0 EU/mg |
| 偶联 | Unconjugated |
| 基因ID | |
| Uniprot ID | |
| 靶点 | CTLA-4/CD152 |
| 分子量 | 148 kDa |
| CAS No. | 477202-00-9 |
| 密度 | no data available |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 同型 | Human IgG1 kappa |
| 推荐同型对照 |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
将CD4+T细胞与DC细胞共培养,构建人类混合淋巴细胞反应模型。设置对照组、氯喹(CQ)处理组、CQ+Ipilimumab处理组,培养6天后收集上清。通过ELISA实验检测到,CQ抑制IFN-γ分泌,而Ipilimumab能逆转CQ的抑制作用。
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多